Cambridge, MA-based Alnylam Pharmaceuticals (NASDAQ: [[ticker:ALNY]]) said today it has acquired a load of intellectual property that includes more than 100 active patent applications and 16 issued patents worldwide from Langhorne, PA-based Nucleonics. The intellectual property is meant to strengthen Alnylam’s grip on its right to develop drugs using RNA Interference technology, or gene silencing. Terms of the purchase weren’t disclosed, although Alnylam said it still expects to finish the year with more than $500 million in cash and investments, as it previously forecast.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
